Vanda Pharmaceuticals (VNDA) announced the first dose in the first-in-human clinical trial to evaluate the safety and tolerability of VCA-894A, an antisense oligonucleotide therapeutic, for a patient with a rare variant in the IGHMBP2 gene causing Charcot-Marie-Tooth disease Type 2S.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VNDA:
- Vanda Approves Key Proposals at Annual Meeting
- Vanda Pharmaceuticals assumed with an Overweight at Cantor Fitzgerald
- Vanda Pharmaceuticals: Strong Financial Performance and Strategic Growth Justify Buy Rating
- Vanda Pharmaceuticals’ Earnings Call: Growth Amid Challenges
- Vanda Pharmaceuticals Reports Q1 2025 Financial Results